Zenas BioPharma, Inc. Common Stock ZBIO
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-07T08:09:50.173Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-06T21:00:05.763782258Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-07T08:06:19.307467+00:00
Zenas BioPharma, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 20.54 | 299.5% | 36.0% | |||
| 25Δ | 23.02 | 237.6% | 27.2% | |||
| 30Δ | 24.96 | 192.0% | 20.3% | |||
| 35Δ | 30.87 | 87.0% | 12.8% | 26.00 | 178.7% | 17.6% |
| 40Δ | 29.85 | 83.0% | 9.9% | 27.01 | 166.1% | 14.9% |
| 45Δ | 29.23 | 83.8% | 8.9% | 28.03 | 153.5% | 12.3% |
| 50Δ | 28.62 | 84.7% | 8.0% | 29.04 | 140.9% | 9.6% |
| 55Δ | 28.00 | 85.5% | 7.0% | 30.06 | 129.0% | 7.1% |
| 60Δ | 27.38 | 86.4% | 6.0% | 31.14 | 128.4% | 6.1% |
| 65Δ | 26.77 | 87.2% | 5.0% | 32.21 | 127.7% | 5.1% |
| 70Δ | 26.15 | 88.0% | 4.1% | 33.28 | 127.1% | 4.1% |
| 75Δ | 25.53 | 88.9% | 3.1% | 34.35 | 126.5% | 3.1% |
| 80Δ | 24.89 | 89.2% | 2.2% | 36.16 | 130.4% | 2.3% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 20.54
- IV
- 299.5%
- B/E move
- 36.0%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 23.02
- IV
- 237.6%
- B/E move
- 27.2%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 24.96
- IV
- 192.0%
- B/E move
- 20.3%
35Δ
- Pseudo strike
- 30.87
- IV
- 87.0%
- B/E move
- 12.8%
- Pseudo strike
- 26.00
- IV
- 178.7%
- B/E move
- 17.6%
40Δ
- Pseudo strike
- 29.85
- IV
- 83.0%
- B/E move
- 9.9%
- Pseudo strike
- 27.01
- IV
- 166.1%
- B/E move
- 14.9%
45Δ
- Pseudo strike
- 29.23
- IV
- 83.8%
- B/E move
- 8.9%
- Pseudo strike
- 28.03
- IV
- 153.5%
- B/E move
- 12.3%
50Δ
- Pseudo strike
- 28.62
- IV
- 84.7%
- B/E move
- 8.0%
- Pseudo strike
- 29.04
- IV
- 140.9%
- B/E move
- 9.6%
55Δ
- Pseudo strike
- 28.00
- IV
- 85.5%
- B/E move
- 7.0%
- Pseudo strike
- 30.06
- IV
- 129.0%
- B/E move
- 7.1%
60Δ
- Pseudo strike
- 27.38
- IV
- 86.4%
- B/E move
- 6.0%
- Pseudo strike
- 31.14
- IV
- 128.4%
- B/E move
- 6.1%
65Δ
- Pseudo strike
- 26.77
- IV
- 87.2%
- B/E move
- 5.0%
- Pseudo strike
- 32.21
- IV
- 127.7%
- B/E move
- 5.1%
70Δ
- Pseudo strike
- 26.15
- IV
- 88.0%
- B/E move
- 4.1%
- Pseudo strike
- 33.28
- IV
- 127.1%
- B/E move
- 4.1%
75Δ
- Pseudo strike
- 25.53
- IV
- 88.9%
- B/E move
- 3.1%
- Pseudo strike
- 34.35
- IV
- 126.5%
- B/E move
- 3.1%
80Δ
- Pseudo strike
- 24.89
- IV
- 89.2%
- B/E move
- 2.2%
- Pseudo strike
- 36.16
- IV
- 130.4%
- B/E move
- 2.3%
Options history
Table
| Date | IV (%) |
|---|---|
| 88.30% | |
| 84.29% | |
| 86.62% | |
| 84.32% | |
| 87.68% | |
| 91.03% | |
| 92.49% | |
| 87.67% | |
| 90.97% | |
| 92.11% |
Biotechnology
ZLAB
Description unavailable
More →ZNTL
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapies for the treatment of various cancers.…
More →ZURA
Zura Bio Limited (Ticker: ZURA) is a biotechnology firm dedicated to developing breakthrough therapies for autoimmune disorders and rare diseases. The company features a diverse…
More →ZVRA
Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The…
More →ZYME
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops and markets biotherapeutic products for the treatment of cancer. The company is headquartered in…
More →AARD
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the…
More →